SCYNEXIS, Inc. Receives Merial Research Collaboration Milestone Payment

RESEARCH TRIANGLE PARK, N.C. & DULUTH, Ga.--(BUSINESS WIRE)--Merial Limited and SCYNEXIS, Inc. announced today that SCYNEXIS has earned a payment for meeting certain milestones in its multi-year research collaboration with Merial Limited, which began in 2005. SCYNEXIS, a premier drug discovery and development company, focuses considerable medicinal chemistry, advanced biological screening, bioanalytical and ADMET efforts towards Merial’s animal health discovery efforts.

MORE ON THIS TOPIC